News - Page 76 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Post published:January 13, 2023
Post category:Press Release

Read more about the article atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917

Post published:January 12, 2023
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Resignation of Board Member

Bright Minds Biosciences Announces Resignation of Board Member

Post published:January 12, 2023
Post category:Press Release

Read more about the article Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses

Post published:January 12, 2023
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: December 2022

Psychedelic Research Bulletin: December 2022

Post published:January 12, 2023
Post category:Psychedelics Research Review

Read more about the article Optimi Health Announces Re-Appointments to Board of Directors

Optimi Health Announces Re-Appointments to Board of Directors

Post published:January 12, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Post published:January 12, 2023
Post category:Press Release

Read more about the article PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation

Post published:January 8, 2023
Post category:Press Release

Read more about the article Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications

Post published:January 7, 2023
Post category:Psychedelic Bulletin

Read more about the article GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Post published:January 7, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.